No Data
Morgan Stanley Maintains Bicycle Therapeutics(BCYC.US) With Hold Rating, Cuts Target Price to $4.45
Needham Reaffirms Their Buy Rating on Bicycle Therapeutics (BCYC)
RBC Capital Maintains Bicycle Therapeutics(BCYC.US) With Hold Rating, Cuts Target Price to $5
Truist Financial Maintains Bicycle Therapeutics(BCYC.US) With Hold Rating, Cuts Target Price to $7
A Quick Look at Today's Ratings for Bicycle Therapeutics(BCYC.US), With a Forecast Between $7 to $15
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Irhythm Technologies (IRTC) and Bicycle Therapeutics (BCYC)